T. Rowe Price reports 5.46M-share stake in Kymera (KYMR)

Rhea-AI Filing Summary

Kymera Therapeutics: T. Rowe Price Investment Management, Inc. reports beneficial ownership of 5,460,257 shares of common stock, equal to 6.7% as of 03/31/2026. The filing "hereby declares and affirms that the filing of shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."

The filing lists sole voting power of 5,318,875 shares and sole dispositive power of 5,460,257 shares. The signature block is dated 05/15/2026.

Insights

Institutional Ownership Analyst

Large passive position reported; ownership near single-digit stake.

T. Rowe Price Investment Management, Inc. is shown with 5,460,257 shares representing 6.7% of common stock as of 03/31/2026. This size is commonly disclosed for regulatory transparency and may reflect aggregated client accounts managed by the firm.

The filing includes specific voting and dispositive power counts, and the firm includes a standard disclaimer denying beneficial ownership in the signature block. Subsequent filings could clarify whether the stake is passive under Schedule 13G criteria.

Corporate Governance Counsel

Disclosure follows Schedule 13G format with an ownership denial clause.

The report lists sole voting power of 5,318,875 and sole dispositive power of 5,460,257. The filer’s statement that the filing "shall not be construed as an admission" is a common legal qualifier regarding beneficial ownership assertions.

Stakeholders may watch for any amendment converting this to a Schedule 13D or additional disclosures if the firm’s intent or control changes; timing and triggers are not specified in the excerpt.

Key Figures

Shares beneficially owned: 5,460,257 shares Percent of class: 6.7% Sole voting power: 5,318,875 shares +2 more

5 metrics

Shares beneficially owned 5,460,257 shares Amount beneficially owned reported in Item 4 as of <date>03/31/2026</date>

Percent of class 6.7% Percent of class reported in Item 4 as of <date>03/31/2026</date>

Sole voting power 5,318,875 shares Sole power to vote or to direct the vote (Item 4(i))

Sole dispositive power 5,460,257 shares Sole power to dispose or to direct disposition (Item 4(iii))

Signature date 05/15/2026 Signature block date

Key Terms

Schedule 13G, beneficial ownership, sole dispositive power, sole voting power

4 terms

Schedule 13G regulatory

"Item 1. (a) Name of issuer: KYMERA THERAPEUTICS INC"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficial ownership regulatory

"Item 4. (a) Amount beneficially owned: 5460257"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

sole dispositive power regulatory

"(iii) Sole power to dispose or to direct the disposition of: 5460257"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

sole voting power regulatory

"(i) Sole power to vote or to direct the vote: 5318875"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 10:06 AM Learn about SEC filing dates

FAQ

What stake does T. Rowe Price report in KYMR?

T. Rowe Price reports 5,460,257 shares (6.7%) of KYMERA THERAPEUTICS common stock as of 03/31/2026. The filing also lists sole voting power of 5,318,875 shares and sole dispositive power of 5,460,257 shares.

Does T. Rowe Price claim beneficial ownership of KYMR shares?

The filing includes a verbatim qualifier: "hereby declares and affirms that the filing of shall not be construed as an admission that Price Investment Management is the beneficial owner..., which beneficial ownership is expressly denied." That statement appears in the signature block.

What reporting date and signature date appear in the filing?

The ownership figures are presented as of 03/31/2026, and the form is signed by Ellen York with a signature date of 05/15/2026. Both dates are shown in the provided excerpt.

What powers over the shares does T. Rowe Price report for KYMR?

The excerpt shows sole voting power of 5,318,875 shares and sole dispositive power of 5,460,257 shares. No shared voting or dispositive power is reported in the excerpt.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

KYMERA THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

501575104

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 501575104

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,318,875.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,460,257.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,460,257.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.7 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: KYMERA THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 2472
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 501575104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5460257
(b)	Percent of class: 6.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5318875
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5460257
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	05/15/2026